|

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

RECRUITINGSponsored by Mayo Clinic
Actively Recruiting
SponsorMayo Clinic
Started2023-11-02
Est. completion2026-12-01
Eligibility
Age1 Year+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06600659

Summary

This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

Eligibility

Age: 1 Year+Healthy volunteers accepted
Inclusion Criteria:

* Followed by pediatric hematology/oncology
* Receiving recombinant Erwinia asparaginase for treatment of malignancy

Exclusion Criteria:

* Patients \< 1 year of age
* Patients who have previously received recombinant Erwinia asparaginase within the past two weeks

Conditions3

Acute Lymphobkastic LeukemiaCancerHematopoietic and Lymphatic System Neoplasm

Locations1 site

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Clinical Trials Referral Office855-776-0015mayocliniccancerstudies@mayo.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.